<DOC>
	<DOCNO>NCT01482299</DOCNO>
	<brief_summary>This phase II study evaluate RAD001 ( Everolimus ) term 4-month progression-free survival rate ( primary end-point ) response rate , toxicity , overall survival biomarker assessment ( secondary end-points ) patient metastatic recurrent gastric cancer pS6 Ser 240/4 expression . Eligibility criterion include pathologically proven non-resectable adenocarcinoma stomach measurable disease fail previous first-line palliative chemotherapy include fluoropyrimidine platinum high expression pS6 Ser 240/4 . Oral RAD001 ( everolimus ) 10mg daily administer dose adjust accord observed clinical toxicity . Treatment continue disease progression patient 's intolerability study drug . A study require 40 assessable subject decide whether proportion patient free progression 4 month ( 16 week ) , P , less equal 0.1 great equal 0.25 target error rate 0.05 β 0.2 . If number responses 7 le , hypothesis P &gt; = 0.250 reject target error rate 0.200 actual error rate 0.182 . If investigator assume drop-out rate 10 % , total accrual patient 45 .</brief_summary>
	<brief_title>RAD001 Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression</brief_title>
	<detailed_description>Methodology : Prospective , non blind , open label , single center phase II study Criteria evaluation : Assessment response assess radiologically accord RECIST criterion completion two cycle . Evaluation physical examination , chest X-ray , abdomen-pelvis CT scan Safety criterion : Physical examination , vital sign , performance status , CBC , serum chemistry , NCI CTC V.3.0</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>histologically cytologically document stomach adenocarcinoma include adenocarcinoma esophagogastric junction nonresectable disease metastasis recurrent disease curative surgical resection ( See Appendix A ) unidimensionally measurable disease failure 1st line chemotherapy include fluoropyrimidine ( capecitabine , S1 , 5FU , ) platinum ( cisplatin oxaliplatin ) palliative setting ; progression within 6 month chemotherapy High expression pS6 Ser 240/4 ( proportion pS6 Ser 240/4 positive cancer cell immunohistochemistry &gt; 10 % ) Age 20 75 year old Estimated life expectancy 3 month ECOG performance status 2 low Adequate bone marrow function Adequate kidney function Adequate liver function Fasting serum cholesterol ≤ 300 mg/dL AND fast triglyceride ≤ 2.5 X ULN No prior radiation therapy 25 % BM psychological , familial , sociological geographical condition permit medical followup compliance study Women childbearing potential must negative pregnancy test admission Written inform consent Other tumor type adenocarcinoma CNS metastases prior radiation CNS metastases Gastric outlet obstruction intestinal obstruction Evidence active gastrointestinal bleeding Bone lesion sole evaluable disease Past concurrent history neoplasm stomach cancer Pregnant lactate woman , woman childbearing potential employ adequate contraception Other serious illness medical condition Concomitant 4week period administration experimental drug investigation Concomitant chemotherapy , hormonal therapy , immunotherapy Any preexist medical condition sufficient severity prevent full compliance study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>pS6 Ser 240/4</keyword>
	<keyword>RAD001 ( everolimus )</keyword>
	<keyword>second-line treatment</keyword>
	<keyword>advanced gastric cancer</keyword>
</DOC>